Developer docs
API playgroundTry for free, no card

Search company profiles

Granulation Technology

Full company profile

uuid002pvp7

Namestring
Granulation Technology
Legal namestring
Granulation Technology, Inc.
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Granulation Technology, Inc. (GTI / GTI Pharmaceuticals) is a privately held, US-based pharmaceutical contract manufacturing organization founded in 1997 by Ashok G. Nigalaye and headquartered at a 35,000 sq. ft. cGMP facility in Fairfield, New Jersey. The company provides custom granulation, formulation development, analytical services, and commercial-scale manufacturing of oral solid dosage forms (tablets and capsules) for OTC and prescription pharmaceutical products. Its core technical capabilities span wet and dry granulation, encapsulation with capsule banding, tablet compression, film coating, powder blending, and packaging (including blister and pouch), complemented by pre-formulation studies, Quality by Design methodology, API evaluation, bioequivalence management, forced degradation studies, and ICH-aligned stability studies. The company is FDA GDUFA listed, DEA registered to handle Class III-V controlled substances, cGMP compliant, ISO 9001 certified, and holds Kosher and Halal certifications.

The company's commercial portfolio includes three FDA-approved branded generic products: Methocarbamol Tablets (500 mg and 750 mg, approved April 2021), Carisoprodol Tablets (350 mg, approved October 2021), and Prednisone Tablets (5 mg, 10 mg, and 20 mg, approved December 2023). Under the leadership of President Amit Nigalaye (appointed 2017), GTI operates with approximately 25 professionals serving pharmaceutical clients ranging from small businesses to Fortune 500 companies through direct B2B sales relationships. Revenue is generated primarily through project-based contract manufacturing engagements, with pricing negotiated per engagement rather than publicly disclosed. The company has no disclosed external funding, no parent organization, and remains family-owned; its operating footprint is limited to the United States.

Short descriptiontext

Granulation Technology is a privately held US pharmaceutical contract manufacturer in Fairfield, NJ offering custom granulation, formulation, analytical services, and commercial manufacturing of oral solid dosage forms. It also markets three FDA-approved branded generic products and serves clients from SMBs to Fortune 500.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFairfield, United States
HQ citystring
Fairfield
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical contract manufacturing, oral solid dosage forms, granulation services, generic drug manufacturing, cGMP pharmaceutical production
Industry3 codes
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAFAL
Formulation & Preclinical CMC Support (Nonclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing32541
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Pharmaceutical Contract Manufacturing
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Pharmaceutical Manufacturing
TypeOne Time License
Description

Revenue generated from providing contract manufacturing services for pharmaceutical products including granulation, encapsulation, tableting, coating, and packaging of OTC and prescription drugs. The company serves as a CMO (Contract Manufacturing Organization) for small to Fortune 500 pharmaceutical companies.

granulationtech.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components7 values
Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Granulation Technology, Inc. (GTI) is a pharmaceutical contract manufacturing organization that provides custom granulation, formulation development, analytical development, and cGMP-compliant manufacturing of oral solid dosage forms (granules, capsules, tablets, coated tablets) for OTC and prescription drug products. The company also develops, manufactures, and distributes its own FDA-approved generic tablet products including Prednisone, Carisoprodol, and Methocarbamol tablets.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Successfully serving clients since 1997
+1 more record
Product overview1 text field

Granulation Technology, Inc. is a pharmaceutical manufacturing company offering a portfolio of FDA-approved tablet products and contract manufacturing services. The company manufactures and distributes three branded generic drug products: Prednisone Tablets (5 mg, 10 mg, 20 mg), Carisoprodol Tablets (350 mg), and Methocarbamol Tablets (500 mg, 750 mg) in various count sizes. These pharmaceutical tablets are supported by comprehensive contract development and manufacturing services including wet and dry granulation, encapsulation, tableting (compression), film coating, capsule banding, blending, and packaging of tablets and powders. The company also provides formulation development for immediate and controlled release oral solid dosage forms, analytical development services including method validation and stability studies, and product development solutions encompassing pre-formulation studies, pharmacovigilance, and API evaluation. The company operates as a FDA GDUFA listed facility with cGMP manufacturing capabilities serving clients from small to Fortune 500 companies.

Product and service2 records
1Contract Pharmaceutical Manufacturing Services
CategoryContract Pharmaceutical Manufacturing
Description

cGMP contract manufacturing services for oral solid dosage forms including wet and dry granulation, encapsulation (with capsule banding), tablet compression, film coating, powder blending, and packaging (tablet, powder, pouch, and blister). Services cover OTC and prescription products, with DEA registration supporting Schedule III-V controlled substances. Targeted at pharmaceutical companies needing FDA-compliant manufacturing partners.

2Product Development Services
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

US-based CDMO offering oral solid dose development and manufacturing, analytical services, and stability testing. Most directly comparable mid-market peer to GTI on service mix and customer segment.

TypeDirect peer
Description

Specialty CDMO providing oral solid dose formulation development, analytical services, and clinical/commercial manufacturing for pharma clients. Strong overlap with GTI's granulation, tableting, and packaging services.

3Pharmaceutics International Inc (Pii)
TypeDirect peer
Description

US-based CDMO with cGMP oral solid dose manufacturing, pre-formulation, formulation development, and analytical services. Near-identical capability profile to GTI's full-stack offering.

TypeDirect peer
Description

Specialty CDMO focused on oral solid dose dosage form development and manufacturing (including controlled substance handling), serving pharma from preclinical through commercial. Closely aligned with GTI's core competency.

TypeBroad incumbent
Description

Swiss-headquartered CDMO with global oral solid dose manufacturing footprint including US sites. Comparable offering on tableting, granulation, encapsulation, and packaging for pharma clients worldwide.

6Particle Sciences (Lubrizol Life Science)
TypeDirect peer
Description

CDMO providing formulation development, analytical services, and complex generic drug product development including oral solids. Overlaps with GTI on formulation, pre-formulation, and contract manufacturing.

TypeBroad incumbent
Description

Global large-scale CDMO with extensive oral solid-dose, granulation, encapsulation, and tableting capabilities serving pharma and biotech. Highly comparable offering to GTI but at vastly greater scale and multi-site footprint.

TypeBroad incumbent
Description

Acquired Patheon to become one of the largest pharmaceutical CDMOs globally, offering oral solid dose, sterile, and API services. Overlaps with GTI on formulation, granulation, and commercial-scale manufacturing.

TypeEmerging player
Description

US-based specialty pharma CDMO/manufacturer with cGMP oral solid dose capabilities including 3D-printed formulations. Comparable in scale and service offering to GTI with differentiated technology.

TypeDirect peer
Description

US-based CDMO offering aseptic fill-finish and increasingly oral solid dose development and manufacturing. Adjacent CDMO serving similar pharma customers with overlapping regulatory/compliance profile.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature13 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Granulation Technology

Pharmaceutical Contract Manufacturinggranulationtech.com

Granulation Technology is a privately held US pharmaceutical contract manufacturer in Fairfield, NJ offering custom granulation, formulation, analytical services, and commercial manufacturing of oral solid dosage forms. It also markets three FDA-approved branded generic products and serves clients from SMBs to Fortune 500.

What Granulation Technology does

Granulation Technology, Inc. (GTI / GTI Pharmaceuticals) is a privately held, US-based pharmaceutical contract manufacturing organization founded in 1997 by Ashok G. Nigalaye and headquartered at a 35,000 sq. ft. cGMP facility in Fairfield, New Jersey. The company provides custom granulation, formulation development, analytical services, and commercial-scale manufacturing of oral solid dosage forms (tablets and capsules) for OTC and prescription pharmaceutical products. Its core technical capabilities span wet and dry granulation, encapsulation with capsule banding, tablet compression, film coating, powder blending, and packaging (including blister and pouch), complemented by pre-formulation studies, Quality by Design methodology, API evaluation, bioequivalence management, forced degradation studies, and ICH-aligned stability studies. The company is FDA GDUFA listed, DEA registered to handle Class III-V controlled substances, cGMP compliant, ISO 9001 certified, and holds Kosher and Halal certifications.

The company's commercial portfolio includes three FDA-approved branded generic products: Methocarbamol Tablets (500 mg and 750 mg, approved April 2021), Carisoprodol Tablets (350 mg, approved October 2021), and Prednisone Tablets (5 mg, 10 mg, and 20 mg, approved December 2023). Under the leadership of President Amit Nigalaye (appointed 2017), GTI operates with approximately 25 professionals serving pharmaceutical clients ranging from small businesses to Fortune 500 companies through direct B2B sales relationships. Revenue is generated primarily through project-based contract manufacturing engagements, with pricing negotiated per engagement rather than publicly disclosed. The company has no disclosed external funding, no parent organization, and remains family-owned; its operating footprint is limited to the United States.

Granulation Technology firmographics

Firmographics
Name
Granulation Technology
Legal name
Granulation Technology, Inc.
Website
https://granulationtech.com
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
11–50 employees
Short description
Granulation Technology is a privately held US pharmaceutical contract manufacturer in Fairfield, NJ offering custom granulation, formulation, analytical services, and commercial manufacturing of oral solid dosage forms. It also markets three FDA-approved branded generic products and serves clients from SMBs to Fortune 500.
Ownership category
akta.pro rank

Granulation Technology industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAIABAI
Contract Development & Manufacturing for Generics (CDMO/CMO)
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAGAFAL
Formulation & Preclinical CMC Support (Nonclinical)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)

Keywords

  • Pharmaceutical contract manufacturing
  • Oral solid dosage forms
  • Granulation services
  • Generic drug manufacturing
  • CGMP pharmaceutical production

Where Granulation Technology is headquartered

Location

Headquarters

HQ city
Fairfield
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Granulation Technology business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain, Others

Revenue model

  1. Contract Pharmaceutical Manufacturing: Revenue generated from providing contract manufacturing services for pharmaceutical products including granulation, encapsulation, tableting, coating, and packaging of OTC and prescription drugs. The company serves as a CMO (Contract Manufacturing Organization) for small to Fortune 500 pharmaceutical companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Granulation Technology product offering

Product offering

Core offering

Granulation Technology, Inc. (GTI) is a pharmaceutical contract manufacturing organization that provides custom granulation, formulation development, analytical development, and cGMP-compliant manufacturing of oral solid dosage forms (granules, capsules, tablets, coated tablets) for OTC and prescription drug products. The company also develops, manufactures, and distributes its own FDA-approved generic tablet products including Prednisone, Carisoprodol, and Methocarbamol tablets.

Product overview

Granulation Technology, Inc. is a pharmaceutical manufacturing company offering a portfolio of FDA-approved tablet products and contract manufacturing services. The company manufactures and distributes three branded generic drug products: Prednisone Tablets (5 mg, 10 mg, 20 mg), Carisoprodol Tablets (350 mg), and Methocarbamol Tablets (500 mg, 750 mg) in various count sizes. These pharmaceutical tablets are supported by comprehensive contract development and manufacturing services including wet and dry granulation, encapsulation, tableting (compression), film coating, capsule banding, blending, and packaging of tablets and powders. The company also provides formulation development for immediate and controlled release oral solid dosage forms, analytical development services including method validation and stability studies, and product development solutions encompassing pre-formulation studies, pharmacovigilance, and API evaluation. The company operates as a FDA GDUFA listed facility with cGMP manufacturing capabilities serving clients from small to Fortune 500 companies.

Differentiator

Problem solved

Functional benefit

Products and services

  • Contract Pharmaceutical Manufacturing Services cGMP contract manufacturing services for oral solid dosage forms including wet and dry granulation, encapsulation (with capsule banding), tablet compression, film coating, powder blending, and packaging (tablet, powder, pouch, and blister). Services cover OTC and prescription products, with DEA registration supporting Schedule III-V controlled substances. Targeted at pharmaceutical companies needing FDA-compliant manufacturing partners.
  • Product Development Services

Quantifiable outcome

  • Successfully serving clients since 1997
  • +1 more outcomes

Companies that use Granulation Technology

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Granulation Technology technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature13 records

Granulation Technology partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves7 records

Expansion highlights3 records

Granulation Technology competitors and assessment

Company assessment

Direct peers

  • Alcami Corporation: US-based CDMO offering oral solid dose development and manufacturing, analytical services, and stability testing. Most directly comparable mid-market peer to GTI on service mix and customer segment.
  • Metrics Contract Services: Specialty CDMO providing oral solid dose formulation development, analytical services, and clinical/commercial manufacturing for pharma clients. Strong overlap with GTI's granulation, tableting, and packaging services.
  • Pharmaceutics International Inc (Pii): US-based CDMO with cGMP oral solid dose manufacturing, pre-formulation, formulation development, and analytical services. Near-identical capability profile to GTI's full-stack offering.
  • Halo Pharma: Specialty CDMO focused on oral solid dose dosage form development and manufacturing (including controlled substance handling), serving pharma from preclinical through commercial. Closely aligned with GTI's core competency.
  • Particle Sciences (Lubrizol Life Science): CDMO providing formulation development, analytical services, and complex generic drug product development including oral solids. Overlaps with GTI on formulation, pre-formulation, and contract manufacturing.
  • Lifecore Biomedical: US-based CDMO offering aseptic fill-finish and increasingly oral solid dose development and manufacturing. Adjacent CDMO serving similar pharma customers with overlapping regulatory/compliance profile.

Broad incumbents

  • Siegfried Holding: Swiss-headquartered CDMO with global oral solid dose manufacturing footprint including US sites. Comparable offering on tableting, granulation, encapsulation, and packaging for pharma clients worldwide.
  • Catalent: Global large-scale CDMO with extensive oral solid-dose, granulation, encapsulation, and tableting capabilities serving pharma and biotech. Highly comparable offering to GTI but at vastly greater scale and multi-site footprint.
  • Thermo Fisher Scientific (Patheon Pharma Services): Acquired Patheon to become one of the largest pharmaceutical CDMOs globally, offering oral solid dose, sterile, and API services. Overlaps with GTI on formulation, granulation, and commercial-scale manufacturing.

Emerging players

  • Aprecia Pharmaceuticals: US-based specialty pharma CDMO/manufacturer with cGMP oral solid dose capabilities including 3D-printed formulations. Comparable in scale and service offering to GTI with differentiated technology.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Granulation Technology social profiles

Digital presence

Granulation Technology compliance and trust

Trust signal

Compliance6 records

Granulation Technology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Granulation Technology leadership team

Management profile

Number of profiles

Profiles1 record

Granulation Technology funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Granulation Technology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Granulation Technology

What does Granulation Technology do?

Granulation Technology, Inc. (GTI) is a pharmaceutical contract manufacturing organization that provides custom granulation, formulation development, analytical development, and cGMP-compliant manufacturing of oral solid dosage forms (granules, capsules, tablets, coated tablets) for OTC and prescription drug products. The company also develops, manufactures, and distributes its own FDA-approved generic tablet products including Prednisone, Carisoprodol, and Methocarbamol tablets.

Is Granulation Technology a public or private company?

Granulation Technology is a private company. It is classified as family owned and is currently operating.

When was Granulation Technology founded?

Granulation Technology was founded in 1997. It employs 11 to 50 people.

Where is Granulation Technology based?

Granulation Technology is headquartered in Fairfield, United States, in the North America region.

How does Granulation Technology make money?

One revenue line is on record: contract Pharmaceutical Manufacturing.

Who are Granulation Technology's main competitors?

Direct peers on record are Alcami Corporation, Metrics Contract Services, Pharmaceutics International Inc (Pii), Halo Pharma, Particle Sciences (Lubrizol Life Science) and Lifecore Biomedical. Broad incumbents are Siegfried Holding, Catalent and Thermo Fisher Scientific (Patheon Pharma Services). Aprecia Pharmaceuticals is listed as an emerging player.

Does Granulation Technology have an API?

No public API is recorded for Granulation Technology.

What industry is Granulation Technology in?

Granulation Technology's product category is Pharmaceutical Contract Manufacturing. Its primary akta.pro industry code is HLAIABAI, Contract Development & Manufacturing for Generics (CDMO/CMO), with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 325412 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales